Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Dec 1;9(12):e113936.
doi: 10.1371/journal.pone.0113936. eCollection 2014.

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis

Sara Llufriu  1 , María Sepúlveda  1 , Yolanda Blanco  1 , Pedro Marín  2 , Beatriz Moreno  1 , Joan Berenguer  3 , Iñigo Gabilondo  1 , Eloy Martínez-Heras  1 , Nuria Sola-Valls  1 , Joan-Albert Arnaiz  4 , Enrique J Andreu  5 , Begoña Fernández  1 , Santi Bullich  1 , Bernardo Sánchez-Dalmau  6 , Francesc Graus  1 , Pablo Villoslada  1 , Albert Saiz  1
Affiliations
Clinical Trial

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis

Sara Llufriu et al. PLoS One. .

Abstract

Objective: Uncontrolled studies of mesenchymal stem cells (MSCs) in multiple sclerosis suggested some beneficial effect. In this randomized, double-blind, placebo-controlled, crossover phase II study we investigated their safety and efficacy in relapsing-remitting multiple sclerosis patients. Efficacy was evaluated in terms of cumulative number of gadolinium-enhancing lesions (GEL) on magnetic resonance imaging (MRI) at 6 months and at the end of the study.

Methods: Patients unresponsive to conventional therapy, defined by at least 1 relapse and/or GEL on MRI scan in past 12 months, disease duration 2 to 10 years and Expanded Disability Status Scale (EDSS) 3.0-6.5 were randomized to receive IV 1-2×10(6) bone-marrow-derived-MSCs/Kg or placebo. After 6 months, the treatment was reversed and patients were followed-up for another 6 months. Secondary endpoints were clinical outcomes (relapses and disability by EDSS and MS Functional Composite), and several brain MRI and optical coherence tomography measures. Immunological tests were explored to assess the immunomodulatory effects.

Results: At baseline 9 patients were randomized to receive MSCs (n = 5) or placebo (n = 4). One patient on placebo withdrew after having 3 relapses in the first 5 months. We did not identify any serious adverse events. At 6 months, patients treated with MSCs had a trend to lower mean cumulative number of GEL (3.1, 95% CI = 1.1-8.8 vs 12.3, 95% CI = 4.4-34.5, p = 0.064), and at the end of study to reduced mean GEL (-2.8±5.9 vs 3±5.4, p = 0.075). No significant treatment differences were detected in the secondary endpoints. We observed a non-significant decrease of the frequency of Th1 (CD4+ IFN-γ+) cells in blood of MSCs treated patients.

Conclusion: Bone-marrow-MSCs are safe and may reduce inflammatory MRI parameters supporting their immunomodulatory properties. ClinicalTrials.gov NCT01228266.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: SL, MS, YB, PM, BM, JB, IG, EMH, NSV, JAA, JA, BF, SB, BSD and FG have nothing to declare. PV has received consultancy fees from Novartis, Roche, Neurotek, Heidelberg Engineering, Digna Biotech, Bionure and TFS and research grants from Novartis, Roche and Digna Biotech, and is founder and holds stocks in Bionure. AS has received compensation for consulting services and speaking from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd and Novartis. Dr. Pablo Villoslada, co-author of the paper, is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to PLOS ONE Editorial policies and criteria.

Figures

Figure 1
Figure 1. Study profile.
Figure 2
Figure 2. Relapses and gadolinium-enhancing lesions during the study.
Abbreviations: GEL  =  gadolinium-enhancing lesions; MSCs  =  mesenchymal stem cells; NA  =  not available; Scr  =  screening.
Figure 3
Figure 3. Effects of MSCs in T and B cell population frequency in blood.
Results are shown as percentages respect to the referring cell population (Th1, Th17, CD19 and Treg) and not referred to the total lymphocyte counts. Treatment with mesenchymal stem cells showed a non-significant decrease of the Th1/Th17 populations, increase in regulatory B cells (B reg) population and no changes regarding natural (Nat T reg) and induced (Ind T reg) regulatory T cells populations. Percentage of each population is shown in the graphics regarding the type of therapy, placebo (P) or mesenchymal stem cells (MSCs) and period of treatment, 1 (first period, from month 0 to month 6) or 2 (second period, from month 6 to 12 months).
See this image and copyright information in PMC

References

    1. Uccelli A, Laroni A, Freedman MS (2011) Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 10:649–656. - PubMed
    1. Rice CM, Kemp K, Wilkins A, Scolding NJ (2013) Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet 382:1204–1213. - PubMed
    1. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, et al. (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 67:1187–1194. - PMC - PubMed
    1. Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, et al. (2010) Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol 227:185–189. - PubMed
    1. Rice CM, Mallam EA, Whone AL, Walsh P, Brooks DJ, et al. (2010) Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther 87:679–685. - PubMed

Publication types

MeSH terms

Associated data